Skip to content

You can have confidence in your biosimilar medicines

Learn more
Switching to biosimilars is safe and effective for patients
Learn more
Previous
Next

Who we are

Biosimilars Canada is a national association representing the biosimilar medicines industry in Canada. We provide leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines, and advocate for policies that support their timely approval, reimbursement, market acceptance and expanded use.

About Biosimilars

As patents for original brand biologic medicines expire other manufacturers can produce new versions called biosimilars. Health Canada authorizes biosimilars for sale using the same rigorous regulatory standards as for all other biologic drugs, and there are no clinically meaningful differences in efficacy and safety between a biosimilar and the original brand biologic medicine.

Resources

Learn more about biosimilars and their benefits for patients and healthcare systems.

Latest news

Biosimilars Canada reappoints Robidoux as Chair

Article from The Center for Biosimilars of the covering the Biosimilars Canada Board Chair and Vice-Chair announcement, and key developments in the Canadian biosimilars landscape.

Read more

Biosimilars Canada Announces Board Chair and Vice-Chair

Biosimilars Canada is pleased to announce the unanimous re-election of Mr. Michel Robidoux, President and General Manager of Sandoz Canada, as Chair of the Biosimilars Canada Board. Mr. Mike Woolcock, a Senior Vice President at Apobiologix, has been unanimously re-elected as Vice-Chair of the Biosimilars Canada Board.
Read more

Success and savings with British Columbia’s biosimilars initiative

Anar Dossa, Director of Pharmacy Services at Pacific Blue Cross, shares the private insurer’s success and savings with biosimilar switching and future plans in this interview with the Not So Different podcast.

Read more